Project Grant R21AI192087
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$427K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $127,980.00 to The Johns Hopkins University for a five-year research project focused on integrating genomic and spatial data to develop more effective and efficient community-based tuberculosis (TB) screening and prevention interventions. The key objectives are to: 1) Refine estimates of subnational TB prevalence by...
This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the establishment of a novel human lung alveolar epithelial cell organoid model to study Mycobacterium tuberculosis (MTB) infection and host innate immune responses. The primary objectives are to develop a physiologically relevant in vitro platform using human bronchoalveolar lavage fluid (BALF) to...
This $450,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of different lung macrophage subsets in the maintenance of tuberculosis (TB) lesions and the local environment of Mycobacterium tuberculosis (MTB) infection. The research team at the University of Arkansas for Medical Sciences will utilize novel metabolic analysis and spatial...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...